Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000289554 is annotated as a "novel transcript, sense intronic to GPN2," meaning it is a transcript with no canonical gene symbol or function, identified on the same DNA strand (sense) and entirely within an intron of the GPN2 gene. Such transcripts are usually discovered through high-throughput RNA sequencing and computational analysis of the transcriptome, and they are not referenced in typical drug target or disease association databases. The function, if any, of this transcript is uncharacterized; it may represent a non-coding RNA or byproduct of transcription rather than a protein-coding gene or regulatory element with medical relevance[1]. As such, there is no evidence for involvement in drug action, disease, or biology beyond its transcriptomic annotation. This entry is likely of interest for transcriptomics benchmarking or annotation, not for drug discovery or therapeutic targeting[1]. Therefore, it should not be considered a therapeutic target or included among well-characterized biological receptors, enzymes, or regulatory proteins.
None (no drugs target this transcript)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, sense intronic to GPN2 (ENSG00000289554).